Mitsubishi Tanabe Pharma Showcases Latest Parkinson's Research at Upcoming 2025 Events
Mitsubishi Tanabe Pharma America, Inc. (MTPA) is set to present pivotal research regarding Parkinson's Disease (PD) at two significant upcoming congresses: the
11th Congress of the European Academy of Neurology (EAN) in Helsinki, Finland, and the
4th Annual Advanced Therapeutics in Movement Related Disorders Congress (ATMRD) in Washington D.C. This year's congresses will take place on June 21-24 and June 27-30, 2025, respectively.
Background on ND0612
The focus of MTPA’s research is the investigational drug ND0612, designed as a
24-hour continuous subcutaneous infusion of liquid levodopa/carbidopa (LD/CD). This innovative approach aims to address the motor fluctuations commonly experienced by individuals with Parkinson's Disease, a neurological condition that affects millions globally.
Dr. Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at MTPA, expressed enthusiasm about participating in both congresses, stating, “Our presence at these meetings reflects our dedication to supporting scientific exchange and sharing insights from our latest research focused on evaluating motor fluctuations in Parkinson's disease.” The congresses will serve as platforms for engaging with the broader neurology community and sharing the latest findings from ongoing clinical studies.
EAN 2025 Presentation Details
At the EAN congress, MTPA will feature an electronic poster (e-poster) that will explore the effects of ND0612 on OFF and ON episodes experienced by patients with motor fluctuations. This research draws from the pivotal
Phase 3 BouNDless study (NCT04006210) and includes findings from a one-year open-label extension phase. The e-poster, titled "
Effect of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (Investigational ND0612) on Motor Fluctuations in the Phase 3 BouNDless Study" will be presented on June 21, between 2:35 PM – 2:40 PM EEST.
ATMRD 2025 Presentation Details
Following the EAN, MTPA will also present at the ATMRD congress, where they will provide insights into patient-reported outcomes assessing quality of life in Parkinson's Disease patients undergoing treatment with ND0612. The presentations will showcase findings derived from the same BouNDless trial, emphasizing the treatment’s effectiveness for managing motor fluctuations. Specific topics include:
- - Dopaminergic Adverse Events associated with ND0612, highlighting the safety profile of the treatment. This will be addressed in the poster titled "Dopaminergic Adverse Events With 24-hour Subcutaneous Infusion of Investigational ND0612" presented by Dr. Huyen Phan, Pharm.D.
- - Quality of Life Considerations, focusing on patient experiences while treated with ND0612. This will be covered in the poster titled "Quality of Life With 24-hour subcutaneous Levodopa/Carbidopa Infusion (Investigational ND0612) QoL Results from a Phase 3, Randomized, Active-Controlled Study" presented by Amanda Goldberg, MPAS, PA-C.
- - Long-Term Efficacy, reviewing the sustained benefits of the treatment after one year as discussed in the poster titled "Long-Term Efficacy of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (Investigational ND0612) for Motor Fluctuations in Parkinson's Disease" by Dr. Rajesh Pahwa, M.D., FAAN.
About Mitsubishi Tanabe Pharma America
Mitsubishi Tanabe Pharma America operates from Jersey City, NJ, as a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation. The company aims to develop and commercialize pharmaceutical products that address critical medical needs in North America, particularly in neurology and other therapeutic areas. MTPA continues to prioritize innovative treatments and patient-centered care, with ongoing research targeting chronic conditions and complex diseases.
For further details about their research activities and corporate initiatives, visit
MTPA's website or follow them on social media platforms like X (formerly Twitter), Facebook, and LinkedIn.
As we look forward to new discoveries and advancements in the treatment of Parkinson's disease through such initiatives, the impact of data shared at these congresses becomes pivotal in shaping the future of therapeutic strategies and improving the quality of life for those affected by this challenging condition.